Literature DB >> 22512900

Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts.

Hans Reinecke1, Thomas E Robey, John L Mignone, Veronica Muskheli, Paul Bornstein, Charles E Murry.   

Abstract

BACKGROUND: Fibrosis around cardiac cell injections represents an obstacle to graft integration in cell-based cardiac repair. Thrombospondin-2 (TSP-2) is a pro-fibrotic, anti-angiogenic matricellular protein and an attractive target for therapeutic knockdown to improve cardiac graft integration and survival.
METHODS: We used a TSP-2 knockout (KO) mouse in conjunction with a fetal murine cardiomyocyte grafting model to evaluate the effects of a lack of TSP-2 on fibrosis, vascular density, and graft size in the heart.
RESULTS: Two weeks after grafting in the uninjured heart, fibrosis area was reduced 4.5-fold in TSP-2 KO mice, and the thickness of the peri-graft scar capsule was reduced sevenfold compared to wild-type (WT). Endothelial cell density in the peri-graft region increased 2.5-fold in the absence of TSP-2, and cardiomyocyte graft size increased by 46% in TSP-2 KO hearts.
CONCLUSIONS: TSP-2 is a key regulator of fibrosis and angiogenesis following cell grafting in the heart, and its absence promotes better graft integration, vascularization, and survival.
SUMMARY: Fibrosis around cardiac cell injections impairs graft integration in cell-based cardiac repair. TSP-2 is a pro-fibrotic, anti-angiogenic matricellular protein. Using a TSP-2-knockout mouse model and cardiac cell transplantation, we found significantly reduced fibrosis and increased endothelial cell density in the peri-graft region. Thus, TSP-2 is an attractive target for therapeutic knockdown to improve cardiac graft integration and survival.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512900      PMCID: PMC3401337          DOI: 10.1016/j.carpath.2012.03.005

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  23 in total

1.  Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts.

Authors:  M G Klug; M H Soonpaa; G Y Koh; L J Field
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity.

Authors:  T R Kyriakides; K J Leach; A S Hoffman; B D Ratner; P Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 3.  The relationship between myocardial extracellular matrix remodeling and ventricular function.

Authors:  Gregory L Brower; Jason D Gardner; Mary F Forman; David B Murray; Tetyana Voloshenyuk; Scott P Levick; Joseph S Janicki
Journal:  Eur J Cardiothorac Surg       Date:  2006-08-28       Impact factor: 4.191

4.  Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion.

Authors:  Satoshi Sezaki; Satoshi Hirohata; Akihiro Iwabu; Keigo Nakamura; Kenichi Toeda; Toru Miyoshi; Hitoshi Yamawaki; Kadir Demircan; Shozo Kusachi; Yasushi Shiratori; Yoshifumi Ninomiya
Journal:  Exp Biol Med (Maywood)       Date:  2005-10

5.  Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure.

Authors:  Jaana Rysä; Hanna Leskinen; Mika Ilves; Heikki Ruskoaho
Journal:  Hypertension       Date:  2005-04-18       Impact factor: 10.190

6.  Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts.

Authors:  H Reinecke; M Zhang; T Bartosek; C E Murry
Journal:  Circulation       Date:  1999-07-13       Impact factor: 29.690

7.  Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice.

Authors:  Azin Agah; Themis R Kyriakides; Paul Bornstein
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

8.  The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice.

Authors:  T R Kyriakides; Y H Zhu; Z Yang; P Bornstein
Journal:  J Histochem Cytochem       Date:  1998-09       Impact factor: 2.479

9.  Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy.

Authors:  Blanche Schroen; Stephane Heymans; Umesh Sharma; W Matthijs Blankesteijn; Saraswati Pokharel; Jack P M Cleutjens; J Gordon Porter; Chris T A Evelo; Rudy Duisters; Rick E W van Leeuwen; Ben J A Janssen; Jacques J M Debets; Jos F M Smits; Mat J A P Daemen; Harry J G M Crijns; Paul Bornstein; Yigal M Pinto
Journal:  Circ Res       Date:  2004-07-29       Impact factor: 17.367

10.  Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis.

Authors:  T R Kyriakides; Y H Zhu; L T Smith; S D Bain; Z Yang; M T Lin; K G Danielson; R V Iozzo; M LaMarca; C E McKinney; E I Ginns; P Bornstein
Journal:  J Cell Biol       Date:  1998-01-26       Impact factor: 10.539

View more
  13 in total

Review 1.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

Review 2.  Matricellular proteins and biomaterials.

Authors:  Aaron H Morris; Themis R Kyriakides
Journal:  Matrix Biol       Date:  2014-03-20       Impact factor: 11.583

Review 3.  Thrombospondin-2 and extracellular matrix assembly.

Authors:  Nicole E Calabro; Nina J Kristofik; Themis R Kyriakides
Journal:  Biochim Biophys Acta       Date:  2014-01-15

4.  Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease.

Authors:  David M Charytan; Robert Padera; Alexander M Helfand; Michael Zeisberg; Xingbo Xu; Xiaopeng Liu; Jonathan Himmelfarb; Angeles Cinelli; Raghu Kalluri; Elisabeth M Zeisberg
Journal:  Int J Cardiol       Date:  2014-07-06       Impact factor: 4.164

5.  Weight Loss Results in Increased Expression of Anti-Inflammatory Protein CRISPLD2 in Mouse Adipose Tissue.

Authors:  Robert M Jackson; Beth A Griesel; Kevin R Short; David Sparling; Willard M Freeman; Ann Louise Olson
Journal:  Obesity (Silver Spring)       Date:  2019-12       Impact factor: 5.002

Review 6.  Thrombospondins: old players, new games.

Authors:  Olga Stenina-Adognravi
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

Review 7.  Thrombospondins: A Role in Cardiovascular Disease.

Authors:  Dimitry A Chistiakov; Alexandra A Melnichenko; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2017-07-17       Impact factor: 5.923

8.  THBS2 Is a Candidate Modifier of Liver Disease Severity in Alagille Syndrome.

Authors:  Ellen A Tsai; Melissa A Gilbert; Christopher M Grochowski; Lara A Underkoffler; He Meng; Xiaojie Zhang; Michael M Wang; Hailu Shitaye; Kurt D Hankenson; David Piccoli; Henry Lin; Binita M Kamath; Marcella Devoto; Nancy B Spinner; Kathleen M Loomes
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-05-26

Review 9.  Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis.

Authors:  Markella Ponticos; Barbara D Smith
Journal:  J Biomed Res       Date:  2013-09-20

10.  Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis in chronic allograft nephropathy.

Authors:  Christoph Daniel; Regina Vogelbacher; Andrea Stief; Christina Grigo; Christian Hugo
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.